Facebook Linkedin RSS Twitter Youtube
Home 2022

Sanofi Pasteur

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance
Artificial Intelligence

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Virtual Becomes Reality for Biopharma Vaccine Development
GENcast

Virtual Becomes Reality for Biopharma Vaccine Development

Sanofi to Expand Seasonal Flu Vaccine Manufacturing Site
Drug Discovery

Sanofi to Expand Seasonal Flu Vaccine Manufacturing Site

Emergent Buys Sanofi Pasteur’s Smallpox Vaccine for Up-to-$125M
Drug Discovery

Emergent Buys Sanofi Pasteur’s Smallpox Vaccine for Up-to-$125M

Sanofi Pasteur Dengue Vaccine Aces Second Phase III Trial
News

Sanofi Pasteur Dengue Vaccine Aces Second Phase III Trial

People in the News
Insights

People in the News

Sanofi Pasteur’s Quadrivalent Flu Vaccine Succeeds in Phase III Pediatric Study
Drug Discovery

Sanofi Pasteur’s Quadrivalent Flu Vaccine Succeeds in Phase III Pediatric Study

CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program
Drug Discovery

CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program

Sanofi Pasteur to Evaluate Leukocare’s Stabilization Technology for Vaccines
Bioprocessing

Sanofi Pasteur to Evaluate Leukocare’s Stabilization Technology for Vaccines

FDA Approves Sanofi Pasteur’s Meningococcal Vaccine for Children Aged 9–23 Months
Drug Discovery

FDA Approves Sanofi Pasteur’s Meningococcal Vaccine for Children Aged 9–23 Months

12Page 1 of 2
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.